
    
      Definition: The phase 2 study will provide important information regarding effects of
      LY900003 on safety and efficacy of patients treated with gemcitabine and carboplatin.
      LY900003 will be given at approximately 2 mg/kg/day for the first 14 days of a 21-day cycle.
      The dose and schedule for LY900003 administration are based on results of prior studies of
      LY900003 and are currently being used in other studies of LY900003. Gemcitabine will be
      administered on Days 1 and 8 at 1250 mg/m2 and carboplatin will be given on Day 1 at AUC 5.
    
  